114433-94-2

Usage

Chemical Properties

Light yellow transparent liquid

InChI:InChI=1/C12H13FO2/c1-8(2)11(14)7-12(15)9-3-5-10(13)6-4-9/h3-6,8H,7H2,1-2H3

Upstream product

• 115-19-5 2-methyl-but-3-yn-2-ol 
• 450-95-3 2-fluoroacetophenone 
• 97-62-1 Ethyl isobutyrate 
• 403-42-9 1-(4-fluorophenyl)ethanone 

Downstream Products

• 114433-95-3 2-[5-(4-fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-1-yl]pyridine 
• 142407-05-4 2-[5-(4-fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-1-yl]quinoline 
• 133258-40-9 2-[5-(4-Fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-1-yl]pyrazine 
• 116645-16-0 5-(4-fluorophenyl)-3-(1-methylethyl)-1-phenyl-1H-pyrazole 
• 1031246-31-7 4-(4-fluorophenyl)-N-methyl-6-(1-methylethyl)-2-pyrimidinamine 
• 124288-20-6 (4R,6R)-6-{2-[5-(4-Fluoro-phenyl)-3-isopropyl-1-naphthalen-1-yl-1H-pyrazol-4-yl]-ethyl}-4-hydroxy-tetrahydro-pyran-2-one 
• 129110-44-7 [4-(4-Fluoro-phenyl)-6-isopropyl-pyrimidin-2-yl]-dimethyl-amine 
• 129110-43-6 2-amino-4-(4-fluorophenyl)-6-isopropylpyrimidine 
• 116645-13-7 2-<2-(1,3-dioxolan-2-yl)ethyl>-1-(4-fluorophenyl)-4-methyl-1,3-pentanedione 
• 133258-52-3 2-[5-(4-Fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-1-yl]benzothiazole 
• 1031246-43-1 4-(4-fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methanesulfonyl)amino]pyrimidine 
• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 147118-37-4 N-[4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide 
• 456-03-1 1-(4-fluorophenyl)propan-1-one 

Relevant academic research and scientific papers

Base-Catalyzed Borylation/B-O Elimination of Propynols and B2pin2 Delivering Tetrasubstituted Alkenylboronates

An efficient approach to tetrasubstituted alkenylboronates via a cascade borylation/B-O elimination of propynols and B2pin2 was disclosed. A series of tetrasubstituted alkenylboronates were readily furnished with this strategy in good yields, with further transformations leading to tetrasubstituted alkenes and β-diketones demonstrating the synthetic potential of the alkenylboronates constructed by this strategy as versatile intermediates in organic synthesis.

Method used for synthesizing rosuvastatin calcium key intermediate

The invention discloses a method used for synthesizing a rosuvastatin calcium intermediate represented by formula I. The reaction route is disclosed in the invention. Raw materials used in the method are low in toxicity; synchronous recycling of used solvents can be realized; expensive materials such as 4-methylmorpholine-N-oxide, TPAP (tetrapropylammonium perruthenate), and DIBAL-H are not used, so that production cost is reduced effectively; reaction conditions are mild; energy consumption is low; no special reaction equipment is needed; operation is simple; one-pot preparation can be realized; and the method is convenient for large-scale production.

Synthetic method of rosuvastatin calcium key intermediate

The invention discloses a synthetic method of a rosuvastatin calcium key intermediate. The synthetic method particularly comprises the following steps: carrying out a condensation reaction between fluoroacetophenone and ethyl isobutyrate under the condition of using sodium as alkali by using isopropyl alcohol as a solvent to prepare 1-(4-fluorophenyl)-4-methyl amyl-1,3-diketone; then carrying out a ring closing reaction between the 1-(4-fluorophenyl)-4-methyl amyl-1,3-diketone and methylguanidine hydrochloride by using isopropanol as a solvent to obtain 4-(4-fluorophenyl)-6-isopropyl-N-methyl pyrimidine-2-amine; carrying out a substitution reaction between the 4-(4-fluorophenyl)-6-isopropyl-N-methyl pyrimidine-2-amine and methanesulfonyl chloride by using dichloromethane as a solvent to obtain 4-(4-fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methanesulfonyl) amino] pyrimidine; finally, carrying out a Vilsmeier reaction between the 4-(4-fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methanesulfonyl) amidogen] pyrimidine and DMF (Dimethyl Formamide) as well as phosphoryl chloride to obtain a target compound. The method disclosed by the invention has the advantages of being simple to operate, low in raw material price, high in availability of used raw materials, mild in reaction conditions, low in equipment requirements and production cost, easy for scale production and the like, and has significance industrial application value.

Preparation method of rosuvastatin calcium key intermediate

The invention discloses a preparation method of a rosuvastatin calcium key intermediate, i.e. a compound as shown in a formula I. The preparation method comprises the following steps: a, carrying out a reaction between fluoroacetophenone and ethyl isobutyrate to prepare a compound as shown in a formula IV; b, carrying out a reaction between the obtained compound IV and methylguanidine hydrochloride as well as potassium hydroxide to obtain a compound as shown in a formula III; c, carrying out a reaction between the compound III and triethylamine as well as methanesulfonyl chloride to prepare a compound as shown in a formula II; d, carrying out a reaction between the compound as shown in the formula II and N,N-dimethylformamide as well as phosphorus oxychloride to obtain the compound as shown in the formula I. A reaction route of the preparation method is as shown in the following: (referring to the specification). The method disclosed by the invention has the advantages of being simple to operate, low in raw material price, high in availability of used raw materials, mild in reaction conditions, low in equipment requirements and production cost, easy for scale production and the like, and has significance industrial application value.

NOVEL COMPOUNDS

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis

Certain trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)ethyl]- or ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones and the corresponding ring-opened acids, esters and N-oxides derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-m

Inhibitors of cholesterol biosynthesis. 2. 1,3,5-Trisbustituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles

A series of 1,3,5-trisubstituted pyrazole mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Since previous studies suggested that the 5-(4-fluorophenyl) and 3-(1-methylethyl) substituents affo

Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis

Certain trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)ethyl]- or ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones and the corresponding ring-opened acids, esters and N-oxides derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-m

TRANS-6-[2-(N-HETEROARYL-3,5-DISUBSTITUTED)PYRAZOL-4-YL)-ETHYL]- OR ETHENYL]TETRAHYDRO-4-HYDROXYPYRAN-2-ONE INHIBITORS OF CHOLESTEROL BIOSYNTHESIS

Certain trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)ethyl]-or ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones and the corresponding ring-opened acids derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-methylglutarylcoenzyme A